

Global Chimeric Antigen Receptor (CAR) T cell Immunotherapy Market Research Report 2017 Analysis and Forecast to 2022

WiseGuyReports.com adds "Chimeric Antigen Receptor (CAR) T cell Immunotherapy Market 2017 Analysis Research Report Forecasting to 2022" reports to its database.

PUNE, INDIA, September 11, 2017
/EINPresswire.com/ -- [Chimeric Antigen Receptor \(CAR\) T cell Immunotherapy Market:](#)

Executive Summary

About half a decade ago, Chimeric Antigen Receptor (CAR) T cell Immunotherapy was considered a dead end with no future but due to the recent advancement, this therapy area is on the brink of becoming a highly promising and possibly a breakthrough treatment for the oncology domain in the upcoming future. As per the latest report, more than 95 companies with 190+ CAR-T therapies are actively working in this field. Out of these, 35+ are pharmaceutical industry giants, developing more than 70 CART immunotherapy products targeting around 28 different antigens.

According to report "Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology, and Pipeline Analysis", there is a continuous uptake of investment for the discovery and development process in the respective field, fueling the research and development process. The pipeline of various companies is loaded with a number of highly promising drugs, out of which 3 drugs in the phase II stage of development. Companies are now developing 27 new generation technologies that can handle adverse events more effectively.

Request Sample Report @ <https://www.wiseguyreports.com/sample-request/2101653-chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and>



As per the details provided in the report, most of the developing therapies are designed to work on CD19 antigen having the maximum targeted antigen share of 27%. With the discontinuation of Juno Therapeutics' drug, JCAR015, other companies are heading forward more aggressively in the race of patent filing. Novartis and Kite Pharma are leading the race and planning to file their products- CTL019 and KTE-C19 respectively- in 2017. The company believes that CTL019 (Novartis) and KTE-C19 (Kite Pharma) will emerge as the most promising therapies.

In last seven years, 58 collaborations have occurred in this therapy area, with 29 Research institutes, hospitals, and 29 other small firms. Various companies collaborated together, such as Bluebird Bio – Viomed and Shire Plc- Precision Bioscience sat a deal price of USD 48 million and USD 1.6 billion respectively, to catalyze their R&D process. Many companies have jumped into the CAR-T cell domain through acquisitions of small firms.

The recently launched report is a complete package covering all the advancements going on in the CAR-T cell immunotherapy arena. It covers highly informative details about the CAR-T therapy pipeline drugs, including product profiling for detailed insight covering all the key players in the field with their technological advancements and collaborations to fuel better therapeutics in the market. The report also provides a complete market scenario about the potential market drivers and possible barriers for the companies looking forward to getting a kick start in the given domain.

Reasons to buy:

The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy.

The report provides information about the pipeline products, pipeline product profiling, collaborations, and acquisitions.

The report covers the Current Prominent Research Areas and Key Players.

Pipeline product coverage based on various stages of development ranging from discovery stage till late stage products.

The report provides complete information about the market drivers, market barriers, and SWOT analysis.

Continued...

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2101653

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/403177442>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.